Tanadopa — Competitive Intelligence Brief

Tanadopa (DOCARPAMINE) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Catecholamine. Area: Neuroscience.

phase 2 Catecholamine Neuroscience Small molecule

Target snapshot

Tanadopa (DOCARPAMINE). Tanadopa works by increasing the levels of norepinephrine in the brain, which can help to improve alertness and attention.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Tanadopa TARGET	DOCARPAMINE		phase 2	Catecholamine
Northera	DROXIDOPA	Lundbeck Na Ltd	marketed	Catecholamine	Muscarinic acetylcholine receptor M1	2014-01-01
Demser	metirosine	Aton Pharma Vpna	marketed	Catecholamine Synthesis Inhibitor [EPC]	Tyrosine 3-monooxygenase	1979-01-01
METYROSINE	METYROSINE		marketed	Catecholamine Synthesis Inhibitor [EPC]		1979-01-01
Dopamine Hydrochloride	DOPAMINE		marketed	Catecholamine	D(1A) dopamine receptor	1974-01-01
Raunormin	DESERPIDINE		marketed	Catecholamine-depleting Sympatholytic	Synaptic vesicular amine transporter	1957-01-01
Norepinephrine Bitartrate In 5% Dextrose	NOREPINEPHRINE	Pfizer	marketed	Catecholamine	alpha-adrenergic receptors, beta-adrenergic receptors	1950-01-01

Recent regulatory actions (last 90 days)

• 2026-03-26 — Norepinephrine Bitartrate In 5% Dextrose · FDA · approved · US · Pfizer

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Catecholamine class)

1. · 2 drugs in this class
2. Lundbeck Na Ltd · 1 drug in this class
3. Pfizer · 1 drug in this class